BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
City of Hope Medical Center, Duarte, California Stanford University, Stanford, California University of Kansas Hospital, Kansas City, Kansas University of Minnesota, Minneapolis, Minnesota Atrium Health Levine Cancer Institute - Morehead, Charlotte, North Carolina Providence Swedish Cancer Institute, Seattle, Washington Last updated November 2025